A cohort study involving 205 gastric adenocarcinoma patients treated with neoadjuvant chemotherapy aimed to improve prognosis prediction. The developed radiomic model, incorporating pre- and post-treatment features, outperformed pathological T stage models. The final radiomic model, integrating radiomic and clinicopathological data, demonstrated superior accuracy in predicting 3-year survival. Results suggest the radiomic model could serve as a valuable decision aid tool in clinical practice, offering enhanced prognostic differentiation for patients with gastric cancer post-neoadjuvant chemotherapy.
Journal Article by Wang Y, Tang L (…) Ji J et 9 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.
